Novo Nordisk A/S has been granted US Patent 12594326B2, effective April 7, 2026, covering dual-granule pharmaceutical compositions of GLP-1 peptides and methods of preparation. The patent specifies that granule types are physically separated — one containing the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid without GLP-1 peptide, and the other containing the GLP-1 peptide without the salt — and covers the combined compositions and preparation processes for medical applications.

For pharmaceutical manufacturers and investors in the GLP-1 therapeutics space, this patent establishes intellectual property protection for a novel formulation approach that may differentiate Novo Nordisk's product portfolio. Generic and biosimilar manufacturers should consider this IP landscape when designing around or licensing GLP-1 composition technologies. Healthcare providers and trial sponsors are not directly affected but should be aware of potential formulation exclusivity implications.